Market Overview

Roth Capital Upgraded Peregrine Pharma Following Internal Review of Trial

Related PPHM
New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
US Stock Futures Tumble, China's Shanghai Plunges 8.5%

Roth Capital upgraded Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) following news of an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients.

The firm raised its rating from Neutral to Buy and boosted its price target from $1.25 to $2.70.

Latest Ratings for PPHM

Mar 2014McNicoll Lewis VlakMaintainsBuy
Mar 2013Piper JaffrayInitiates Coverage onOverweight
Jan 2013Roth CapitalUpgradesNeutralBuy

View More Analyst Ratings for PPHM
View the Latest Analyst Ratings

Posted-In: News Upgrades Analyst Ratings


Related Articles (PPHM)

Get Benzinga's Newsletters